Nektar Therapeutics - NKTR Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 1 year target prices for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $3.00 to $21.00. On average, they predict the company's stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 188.7% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.

Nektar Therapeutics' stock was trading at $13.51 at the beginning of 2022. Since then, NKTR stock has decreased by 78.5% and is now trading at $2.91.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NKTR earnings forecast.

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.23. The biopharmaceutical company earned $23.63 million during the quarter, compared to analysts' expectations of $23.31 million. Nektar Therapeutics had a negative net margin of 477.85% and a negative trailing twelve-month return on equity of 81.70%.

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (18.65%), Vanguard Group Inc. (12.32%), Primecap Management Co. CA (8.74%), State Street Corp (4.18%), Bank of New York Mellon Corp (0.91%) and Dimensional Fund Advisors LP (0.67%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends.

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NKTR stock can currently be purchased for approximately $2.91.

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $546.93 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis.

The company employs 740 workers across the globe.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.